Developer · RVPH · United States

Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings is a clinical-stage pharmaceutical company developing next-generation therapeutics for central nervous system, cardiovascular, metabolic, respiratory, and inflammatory diseases. Its lead candidate is brilaroxazine (RP5063), a serotonin-dopamine signaling modulator in late-stage development for schizophrenia and other neuropsychiatric indications.

revivapharma.com ↗

1compound
1program
1indication
Phase 3lead asset

Phase distribution

  • Phase 31

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 1 upcoming · 3 reported

Recently reported

Recent activity

  • Dec 23, 2025ReadoutBrilaroxazine (RP5063)·SchizophreniapendingFDA recommends a confirmatory second Phase 3 (RECOVER-2) before a brilaroxazine schizophrenia NDA.source ↗
  • Jun 2, 2025ReadoutBrilaroxazine (RP5063)·SchizophreniametFull 1-year RECOVER open-label extension positive: durable, dose-related efficacy with favorable long-term safety.source ↗
  • Apr 15, 2024Phase changeBrilaroxazine (RP5063)·SchizophreniaPhase 3Reviva reported FDA alignment on the brilaroxazine schizophrenia NDA path: two positive Phase 3 efficacy studies at Week 4 plus >=12 months of long-term safety data could support an NDA for acute treatment of schizophrenia.source ↗
  • Oct 30, 2023ReadoutBrilaroxazine (RP5063)·SchizophreniametPhase 3 RECOVER met its primary endpoint: brilaroxazine 50 mg cut PANSS total by 10.1 points vs placebo at Week 4 (p<0.001).source ↗
  • Jan 24, 2022Phase changeBrilaroxazine (RP5063)·SchizophreniaPhase 3Pivotal Phase 3 RECOVER trial (NCT05184335) started: 28-day randomized, double-blind, placebo-controlled study of brilaroxazine 15 mg and 50 mg vs placebo in acute schizophrenia, followed by a 52-week open-label extension.source ↗

Competitive landscape

Other companies developing against Reviva Pharmaceuticals Holdings, Inc.'s targets or indications.

Leadership & advisors (6)